The US FDA’s proposed rule on laboratory-developed tests: Impacts on clinical laboratory testing

Ɛsɩpaañɔlɩ yaa kasɩtɩlanɩ kʊnʊŋ kɛ Romanɩɩ kʊnʊŋ nakɛyɛ nɛ pɔyɔɔdʊʊ-kʊ kɛ Ɛsɩpaañɩ ɛjaɖɛ taa nɛ Amerika ajɛyɛɛ sakɩyɛ taa nɛ ɖɔɖɔ kedeŋga taa ajɛyɛ wena paamʊ a-tɛtʊ nɛ ɖoŋ ɖoo canaʊ alɩwaatʊ taa yɔ a-daa.

Ɛsɩpaañɩ kʊnʊŋ lɩna Latɛnɩ cɩkpelʊʊ ŋgʊ pɔyɔɔdʊʊ Cantabrique egitiye taa nɛ Ibérique ɛjaɖɛ ndɩ lɩm cɔɣɔ pɩta yɔ nɛ hayi kiŋ, kɩ-mɩzɩ nɛ kɩtɩŋgʊ Castille kewɩyaɣ walanzɩ pɩkɔ pɩtalɩ Afrika kedeŋga taa nɛ Amerika kedeŋga nɛ Aazii Pasɩfɩkɩɩ taa. Ɖɩnaɣ se kʊnʊŋ ŋgʊ kɩ-tɛ talɩʊ kɛ ajɛyɛ ana ada lɩna Ɛsɩpaañɩ ajɛyɛ tamaasʊ walanzɩ yɔɔ (empire espagnol) kɛ waasɩ hiʊ nɛ kɩgbaanzi nɛ hiʊ nɛ nakʊ alʊwaatʊ taa, canaʊ wɛɛɣ ana ayebina nɛ Romanɩ kʊnʊŋ kɛ ŋgʊ pakɩlɩ kʊ yɔɔdʊʊ nɔnɔ kɛ ajɛyɛ taa yɔ.

Ɛsɩpaañɩ pɩsa lʊlʊʊ taa kʊnʊŋ ŋgʊ kʊ-yɔɔdɩyaa tala ɛzɩ miliiyɔɔ waa 468 nɛ mba palakɩ na kʊ nɛ tʊmɩyɛ kedeŋga taa yɔɔdʊtʊ taa yɔ paba talɩ ɛyaa miliiyɔɔ waa 559. Mbʊ kɩ-kɛ kʊnʊŋ naatozo ŋgʊ kɛ kedeŋga taa yee ɖɩkpaɣ mba panɩʊ kʊ yɔ kɛ Sinii mandarɩnɩ nɛ Ɛnglɩsɩ kʊnʊmɩŋ wayi nɛ kɩ-kɛ naalɛ ŋgʊ yee ɖikpaɣ mba palʊla kʊnʊŋ ŋgʊ kɩ-ta nɛ pɔɔyʊʊ -kʊ yɔ. Ɛsɩpanñɩ kɛ kacalaɣ kʊnʊŋ lɛɛkʊ ŋgʊ ajɛyɛ yɔɔdʊʊ na ɖama yɔɔ nɛ Ɛnglɩsɩ nɛ Fransɩɩ tɔm.